Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Objective. To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4
inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Objective To evaluate the efficacy and safety of apremilast, a novel, orally available small
molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic …

Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …

Background The efficacy and safety of apremilast were assessed in patients with psoriatic
arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3) …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …